Del Ponte A, D'Orazio N, Di Giacomo G, Tritella T, Bitti G, Martines G
Istituto di Medicina Interna, Università, Chieti.
Recenti Prog Med. 1993 Feb;84(2):100-5.
Aim of the study was to observe if the administration of an anorectic drug, d-fenfluramine, in addition to hypocaloric diet, could influence the body composition and adipose mass distribution during a weight decrease programme in 17 obese women. Drug's effects plus diet on body weight changes were compared with those of a "only-diet programme" in another group of 18 obese subjects, sex and age matched. Both groups were observed for a 6-month period. All subjects were selected on the base of Index Body Weight % within 120-200 and without any therapy for other diseases. Blood samples were drawn before, during (3rd month) and after the period of observation for the measurement of OGTT, serum lipids, liver and kidney function parameters, blood cells count. Body weight and height, body composition, waist-to-hip ratio were also evaluated. Results documented: 1) significant reduction of body weight in the group kept on the combined therapy; 2) significant variation of body composition with increment of fat free mass and adipose mass decrease; 3) significant improvement of glucose tolerance, liver and kidney function parameters. In conclusion, our data show beneficial effects of d-fenfluramine on appetite reduction, influencing the carbohydrates assumption and the consequent fat mass loss with a good tolerability of the drug.
本研究的目的是观察在低热量饮食基础上,给予食欲抑制剂d-芬氟拉明是否会对17名肥胖女性在体重减轻计划期间的身体成分和脂肪分布产生影响。将药物联合饮食对体重变化的影响与另一组18名年龄和性别匹配的肥胖受试者的“单纯饮食计划”的影响进行比较。两组均观察6个月。所有受试者均根据体重指数在120 - 200之间且未接受其他疾病治疗的标准进行选择。在观察期之前、期间(第3个月)和之后采集血样,以测量口服葡萄糖耐量试验、血脂、肝肾功能参数和血细胞计数。还评估了体重、身高、身体成分和腰臀比。结果表明:1)联合治疗组体重显著降低;2)身体成分有显著变化,去脂体重增加,脂肪量减少;3)葡萄糖耐量、肝肾功能参数有显著改善。总之,我们的数据显示d-芬氟拉明对降低食欲有有益作用,影响碳水化合物摄入,进而导致脂肪量减少,且该药物耐受性良好。